Markets:

Overview

News

Currencies

International

Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

17.53 +0.82 (+4.91%)

Streaming Delayed Price Updated: 2:18 PM EDT, Mar 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

22 23 Next >

Rivian Automotive, Rocket Lab And Moderna Are Among Top 10 Large-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio? ↗

December 01, 2024

Top performers last week: RIVN, RKLB, SRPT, EXAS, ESTC, ULTA, MRNA, RL, CPRT, SNAP. Any in your portfolio? Citigroup raises price target on ULTA and SNAP.

Via Benzinga

Wall Street's Top 10 Stock Calls This Week - Saturday, Nov. 30 ↗

November 30, 2024

Via Talk Markets

Topics Stocks / Equities

Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On? ↗

November 26, 2024

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global licensing and collaboration agreement with Sarepta Therapeutics Inc. (NASDAQ: SRPT)....

Via Benzinga

J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

November 26, 2024

Via Benzinga

Analyst Expectations For Sarepta Therapeutics's Future ↗

November 25, 2024

Via Benzinga

Peeling Back The Layers: Exploring Sarepta Therapeutics Through Analyst Insights ↗

October 21, 2024

Via Benzinga

Unveiling 15 Analyst Insights On Sarepta Therapeutics ↗

October 21, 2024

Via Benzinga

Arrowhead Launches 25% On A Massive Licensing Deal With Sarepta ↗

November 26, 2024

The deal focuses on four clinical-stage drugs, three preclinical assets and a potential five new targets.

Via Investor's Business Daily

This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday ↗

November 25, 2024

Via Benzinga

Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday ↗

November 07, 2024

Via Benzinga

This McKesson Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗

November 07, 2024

Via Benzinga

Sarepta Therapeutics (SRPT) Q3 2024 Earnings Call Transcript ↗

November 07, 2024

SRPT earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

Analyst Scoreboard: 12 Ratings For Sarepta Therapeutics ↗

October 04, 2024

Via Benzinga

Unveiling 26 Analyst Insights On Sarepta Therapeutics ↗

September 06, 2024

Via Benzinga

How Is The Market Feeling About Sarepta Therapeutics? ↗

August 16, 2024

Via Benzinga

A Closer Look at 28 Analyst Recommendations For Sarepta Therapeutics ↗

August 15, 2024

Via Benzinga

This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

October 21, 2024

Via Benzinga

After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent ↗

October 18, 2024

Public interest groups are urging the FTC to block Novo Holdings' $16.5 billion acquisition of Catalent, citing concerns over reduced competition in critical areas like diabetes, obesity treatments,...

Via Benzinga

Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up ↗

October 18, 2024

The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma.

Via Investor's Business Daily

2 High-Flying Growth Stocks With Massive Upside Potential ↗

October 17, 2024

These innovative drugmakers have potential catalysts ahead.

Via The Motley Fool

Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics ↗

October 03, 2024

These two could become direct competitors relatively soon.

Via The Motley Fool

$100 Invested In This Stock 10 Years Ago Would Be Worth $600 Today ↗

August 12, 2024

Via Benzinga

Smart Money Is Betting Big In SRPT Options ↗

August 08, 2024

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 18, 2024

Via Benzinga

These 2 Biotech Stocks Are Set to Soar ↗

September 13, 2024

Innovative drugmakers developing treatments for conditions with high unmet needs can produce lucrative wins.

Via The Motley Fool

Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy ↗

September 03, 2024

Dyne Therapeutics revealed new clinical data from its Phase 1/2 DELIVER trial of DYNE-251 for Duchenne muscular dystrophy, showing significant increases in dystrophin expression and meaningful...

Via Benzinga

Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building ↗

September 03, 2024

The company is hoping to rival Sarepa's Exondys 51. But three executives just departed on what is calls "unprecedented" test results.

Via Investor's Business Daily

2 Biotech Stocks to Buy Hand Over Fist in August ↗

August 12, 2024

Both of these biotechs are highly innovative companies.

Via The Motley Fool

Warner Bros, Airbnb And Monster Beverage Are Among Top 10 Large Cap Losers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio? ↗

August 11, 2024

These 10 stocks had the biggest drop last week, with McKesson Corporation, BIO-TECHNE Corp, and Warner Bros. Discovery, Inc. being the worst performers.

Via Benzinga

How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics ↗

August 09, 2024

The company is coming up fast with a platform that could take on several of Sarepta's approved treatments.

Via Investor's Business Daily

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

Headline News about Sarepta Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today